Monitoring and Biomarker Targets During a MOTS-C Protocol A MOTS-c dosage protocol without biomarker monitoring is an incomplete intervention
[5] VLCDs carry recognised risks, including electrolyte imbalances and, in rare cases, QT interval prolongation an abnormality in the heart's electrical cycle that has been reported in association with severe caloric restriction and electrolyte disturbance, and which can predispose individuals to dangerous arrhythmias
Disclose use to your GP or pharmacist without delay, and seek urgent medical attention via NHS 111 or 999 if you experience severe abdominal pain, persistent vomiting, dehydration, or symptoms of low blood sugar
[32:51] Andrew Huberman All right
These risks include anemia, neurological disorders, mood changes, and compromised immune function
This has opened up an entirely separate line of neurological research